{
    "clinical_study": {
        "@rank": "26552", 
        "brief_summary": {
            "textblock": "The primary purpose of this protocol is to make arbekacin available for treatment of\n      patients with infections caused by multidrug-resistant organisms when treatment with other\n      antibiotics cannot be used due to unavailability, intolerance, contraindications, or\n      treatment non-response."
        }, 
        "brief_title": "Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria", 
        "condition": "Infection Due to Resistant Organism", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subject is military health care beneficiary at least 18 years of age;\n\n          2. Subject is a Walter Reed National Military Medical Center patient deemed by the\n             primary medical or surgical team as having a bacterial infection of the respiratory\n             tract, bloodstream, skin, soft tissue, bone, or genitourinary tract;\n\n          3. Subject is allergic to or intolerant of antibiotics to which the infective organism\n             is susceptible; Or The use of antibiotics to which the subject's infective organism\n             is susceptible is contraindicated; Or\n\n             Subject's infective organism isolate is a multidrug-resistant (MDR) bacterium defined\n             as any of the following:\n\n               -  Gram-negative bacterium that is non-susceptible to all index antibiotics within\n                  3 or more of 6 antibiotic classes including aminoglycosides (amikacin,\n                  gentamicin, tobramycin), beta-lactam/beta-lactam inhibitor combinations\n                  (piperacillin-tazobactam, amoxicillin-clavulanate), carbapenems (imipenem,\n                  ertapenem), fluoroquinolones (ciprofloxacin, levofloxacin), cephalosporins\n                  (ceftazidime, cefepime, ceftriaxone), and sulbactam (ampicillin-sulbactam);\n\n               -  Extended Spectrum \u03b2-lactamase (ESBL) producing Gram-negative bacterium;\n\n               -  Carbapenemase resistant Enterobacteriaceae;\n\n               -  Cephalosporin resistant Klebsiella species;\n\n               -  Methicillin-resistant Staphylococcus aureus (MRSA);\n\n               -  Vancomycin resistant Enterococcus species;\n\n               -  Staphylococcus aureus that is non-susceptible to vancomycin.\n\n          4. Subject's infective organism is inhibited in vitro by arbekacin at a concentration \u2264\n             4 \u03bcg/mL;\n\n          5. Subject is able to give written or witnessed verbal informed consent [An exception\n             from the general requirements for informed consent can be made based upon the\n             criteria specified in 21 Code of Federal Regulations 50.23 (a and c)];\n\n          6. Subject has adequate venous access for intravenous administration of arbekacin.\n\n        Exclusion Criteria:\n\n          1. Subject has a history of allergy or serious adverse reaction to aminoglycoside\n             antibiotics;\n\n          2. Subject is currently participating in another investigational new drug study."
            }, 
            "gender": "Both", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "August 3, 2012", 
        "id_info": {
            "nct_id": "NCT01659515", 
            "org_study_id": "S-11-0001"
        }, 
        "intervention": {
            "description": "Intravenous arbekacin in a total daily dose of 5-7 mg/kg", 
            "intervention_name": "Arbekacin Sulfate", 
            "intervention_type": "Drug", 
            "other_name": [
                "Arbekacin", 
                "Habekacin"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Habekacin", 
                "Dibekacin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 6, 2014", 
        "location": {
            "contact": {
                "email": "Michael.j.zapor.mil@mail.mil", 
                "last_name": "Michael Zapor, MD, PhD", 
                "phone": "301-677-8124"
            }, 
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20889"
                }, 
                "name": "Walter Reed National Military Medical Center (WRNMMC)"
            }, 
            "investigator": {
                "last_name": "Michael Zapor, MD, PhD", 
                "role": "Principal Investigator"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria", 
        "overall_contact": {
            "email": "Michael.j.zapor.mil@mail.mil", 
            "last_name": "Michael Zapor, MD, PhD", 
            "phone": "301-677-8124"
        }, 
        "overall_contact_backup": {
            "email": "christa.madock@us.army.mil", 
            "last_name": "Christa M Madock", 
            "phone": "(301) 619-4649"
        }, 
        "overall_status": "Available", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01659515"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "U.S. Army Medical Research and Materiel Command", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Meiji Seika Pharma Co., Ltd.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Uniformed Services University of the Health Sciences", 
                    "agency_class": "U.S. Fed"
                }
            ], 
            "lead_sponsor": {
                "agency": "U.S. Army Medical Research and Materiel Command", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "study_design": "N/A", 
        "study_type": "Expanded Access", 
        "verification_date": "March 2014"
    }
}